News
Second-quarter earnings season is in full swing, and the results have been largely resilient so far. So why are stocks ...
Earnings jumped to $1.03 a share, up from $0.60 a year ago, as Emerson ( NYSE: EMR) improved its pretax margin by 570 basis ...
This would indicate a 6% year-over-year growth in earnings and a 3% increase in sales when compared to the previous year’s ...
Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.
Pfizer ( PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 guidance of between $61 to $64 ...
Q2 2025 Management View Dave Cramer, President and CEO, reported sequential improvement in occupancy and contract rates, but ...
22hon MSN
NJR raises 2025 NFEPS guidance to $3.20-$3.30 per share while expanding SAVEGREEN investments
Q3 2025 Management View Stephen D. Westhoven, President and CEO, indicated, "Fiscal 2025 continues to be an excellent year ...
2h
Zacks.com on MSNArbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of +150.00% and +496.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
MannKind (MNKD) delivered earnings and revenue surprises of -100.00% and -2.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Earnings per share is one of the best metrics of a company’s financial health. In this guide, Benzinga discusses the ins and outs of earnings per share (EPS).
Over the last five years, the stock has decreased in 56% of these instances, with a median decline of -3.1% and a maximum ...
The company put up a bottom-line revenue that not only exceeded Wall Street expectations, but also its own history of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results